Although the incidence of metastatic prostate cancer has decreased since recommendations for Prostate-specific Antigen (PSA) exams have increased, it has nevertheless still increased by >2.7% per year since 2012, with the annual burden expected to increase 42% by the year 2025 (Kelly et al., 2018). The gene discussed is KLK3; the disease is metastatic prostate carcinoma.